The National Health Service of England has announced for the first time that it will need to assess the price of the medicines passing through the Cancer Drugs Fund. This coming after the government announced it was having to add a considerable amount of money each year to the pot. Will NICE’s QALY formula for assessing the cost-effectiveness of drugs be merged with the CDF? Learn more here. (Source: Pharmafile, 3/9/14).
You are here: / / Should The Cancer Drug Fund Use NICE’s Cost-Effectiveness Process?